

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Gosse J. ADEMA et al.

Confirmation No.: 8025

Art Unit: 1647

Application No.: 10/777,524

Examiner: B. E. Bunner

Filed: February 11, 2004

For: FDF03 POLYPEPTIDE (AS AMENDED)

DECLARATION OF LEWIS LANIER, PH.D.
PURSUANT TO 37 C.F.R. § 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, Lewis Lanier, declare as follows:

1. I am an expert in the field of immunology, particularly regarding the molecular and cellular biology of discrete hematopoietic cell populations involved in immune responses. I am currently a Professor in the department of Microbiology and Immunology at the University of California at San Francisco and am a consultant for Schering-Plough BioPharma (formerly DNAX). A copy of my curriculum vitae is attached. I am familiar with the contents of the above-referenced patent application.

2. It is my understanding that the pending claims stand rejected because one of ordinary skill in the art would not find an immediate, well-defined, real world use for FDF03 based on the disclosure of the instant specification.

3. The specification discloses that FDF03 is an Ig receptor superfamily member, and its expression is restricted to cells of the myelomonocytic lineage. *See* the specification at page 42, lines 27-31; page 54, lines 18-22 and page 87, line 35 to page 88, line 6. The specification goes on

to identify a specific role for FDF03 as a regulator of hematopoietic cells including those involved in antigen presentation (*e.g.*, monocytes and dendritic cells). *See id.* at page 68, line 35 to page 69, line 3.

4. The specification's description of FDF03 provides an immediate, well-defined, real world use for the protein as a discrete marker for monocytes, macrophages, and other cells of the myelomonocytic lineage. As described in the specification, FDF03 can be used to detect an increase in number of monocytes in a tissue or lymph system and thus indicate the presence of monocyte hyperplasia, tissue or graft rejection, inflammation or an abnormal response to a bacterial or viral infection. *See id.* at page 87, line 35 to page 88, line 6. The selective expression of FDF03 has been confirmed in work described in a peer-reviewed scientific publication. *See* Fournier, et al., *J. Immunol.* 165(3):1197-1209 (2000). As it is selectively expressed on a discrete subpopulation of cells (*i.e.*, the myelomonocytic lineage), the FDF03 protein accurately and immediately serves as a marker for a discrete cell population and is useful in assessing the relative levels of monocytes. Even without identification of a precise function of this protein or an association with a particular disease state, the expression profile disclosed in the specification provides an instant, real world use for the FDF03 protein.


5. The specification's description of FDF03 provides an immediate, well-defined, real world use for the protein as a regulator of antigen presentation in cells of the myelomonocytic lineage. The specification describes the FDF03 protein as one that "likely plays a role in regulation or development of hematopoietic cells, ... *e.g.*, antigen presentation and the resulting effector functions." *See* the specification at page 68, line 37 to page 69, line 3. It is well known that cells of the myelomonocytic lineage participate in antigen presentation. Assays to assess antigen presentation capacity are well known, readily available, and easily performed by one of ordinary skill in the art. Given the restricted expression of the FDF03 protein, its identity as a Ig receptor family member, and its described role in antigen presentation regulation in the instant application, a person of ordinary skill in the art would appreciate the immediate usefulness of the FDF03 protein. The specific usefulness of the FDF03 protein comes from its identity as a regulator of antigen presentation. Whether it positively or negatively regulates antigen presentation and under what

conditions that regulation occurs is certainly interesting, but it is not necessary for the specific and immediate recognition by one of ordinary skill in the art that the FDF03 protein is useful. In other words, regardless of whether FDF03 is a positive or negative regulator of antigen presentation, it is useful as a modulator of this critical aspect of the immune response.

6. Taken together, it is my opinion that the description in the specification provides more than one immediate, well-defined real world use of FDF03 protein as, for example, a discrete marker for cells of the myelomonocytic lineage and as a regulator of antigen presentation in these cells. Therefore, I believe that the description the instant specification discloses these uses in a manner sufficient for one of ordinary skill in the art to appreciate and immediately exploit these uses in a real word context.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Executed at San Francisco, CA on ____ October 8, 2007 ____.



Lewis L. Lanier, Ph.D.

Curriculum Vitae

Lewis L. Lanier

Work Address: University of California San Francisco
Department Microbiology and Immunology
Dept. of Microbiology & Immunology
HSE 1001G, 513 Parnassus Ave., Box 0414
San Francisco, CA 94143-0414

Telephone (415) 514-0829
FAX: (415) 502-8424
e-mail: lewis.lanier@ucsf.edu

Home Address: 229 Juanita Way
San Francisco, CA 94127-1744
Telephone 415-566-9079

Citizenship: U.S.A.

Education:

Ph.D. Microbiology and Immunology, University of North Carolina -Chapel Hill, 1978

B.S. Biology (Microbiology), graduated with High Honors, Virginia Polytechnic Institute and State University, 1975

Special Awards and Honors:

President, American Association of Immunologists, 2006-2007

National Institutes of Health MERIT Grant Award, 2006

Keystone Symposia – Lymphocyte Activation and Signaling, Keynote Address, 2006

American Society for Histocompatibility & Immunogenetics Rose Payne Award, 2005

American Association of Immunologist Distinguished Lecture, 2004

American Cancer Society Research Professorship, 2003

William B Coley Award for Distinguished Research in Basic and Tumor Immunology, Cancer Research Institute, New York, 2002

American Association of Immunologists Distinguished Service Award, 2001

Damon Runyon - Walter Winchell Cancer Fund Postdoctoral Fellowship, 1979-1981

National Research Service Award Fellowship, Cancer Research Center, The University of North Carolina School of Medicine at Chapel Hill, 1978-1979

Virginia Polytechnic Institute and State University Freshman Science Scholarship, 1971

Professional Activities:

President, American Association of Immunologists, 2006-2007

Councilor, American Association of Immunologists, 2001-2008

Chairman and Board Member, United States – NIH- Japan Cooperative Medical Science Program Immunology Board, Board Member – 2004; Chairman, 2005 – 2007

Chairman, National Institutes of Health Center for Scientific Review Special Emphasis Panel, 2001, 2003, 2005, 2006

Member, NIH Special Emphasis Panel, NIAID, Biodefense and Emerging Infectious Diseases Research Opportunities, 2004

Member, National Institutes of Health Center for Scientific Review Immunology, Study Section Boundaries Team, 2002

Chairman and Member, National Institutes of Health Experimental Immunology Study Section, 1994-1999. Chairman, 1997-1999

Member, National Institutes of Health Reviewers Reserve, 1989-1993

Member, Cancer Research Institute, CRI Investigator Award Review Committee, 2003-present

Block Chairman, Program Committee, American Association of Immunologists, 1992-1996

Chairman, Program Committee, American Association of Immunologists, 1997-2000

Program Committee, American Society for Histocompatibility and Immunogenetics, 2001

Nominating Committee, American Association of Immunologists, 1994

Council Member, MidWinter Conference of Immunologists, 1992-1997; 1999-2004

Reviews Editor, *Immunity*, 2002-2004

Editorial Board, *Immunity*, 2001-present

Editorial Committee Member, *Annual Review of Immunology*, 2004-2008

Advisory Editor, *Journal of Experimental Medicine*, 1995-2008

Associate Editor, *Journal of Immunology*, 1986-1991

Transmitting Editor, *International Immunology*, 1988-1997, 2001-2005

Editorial Board, *Immunological Reviews*, 2002-present

Editorial Board, *Clinical Immunology and Immunopathology*, 1989-1995

Editorial Board, *Journal of Clinical Immunology*, 1992-1997

Editorial Board, *Tissue Antigens*, 1990-present

Editorial Board, *Human Immunology*, 1999-present

Editorial Board, *Cellular Immunology*, 2000-2004

Editorial Board, *Cancer Immunology Immunotherapy*, 2005-present

Scientific Advisory Board, Protein Design Labs, 2005-present

Scientific Review Board, Schering Plough Biopharma, 2000-present

Board of Directors, Symphony-Dynamo, 2006-present

Scientific Advisory Board, Entelos, Inc., 2000-present

Scientific Advisory Board, Shanghai Genomics, 2005-present

Scientific Advisory Board, Ginkgo Biomedical Research Institute, 2005-present

Scientific Advisory Board, Avipep, 2005-present

Member, Scientific Advisory Council, Cancer Research Institute, 2006-present

Scientific Advisory Board, Institute Pasteur, Department of Immunology, 2004-present

Scientific Advisory Board, International Histocompatibility Working Group, 1999-present

Damon Runyon – Walter Winchell Cancer Research Fund, Alumni Network, 2000-present

Advisory Committee, XIII International Congress on Histocompatibility and Immunogenetics, 2001-2002

Co-organizer, 33rd MidWinter Conference of Immunologists, Asilomar, CA, 1994

Co-organizer, 40th MidWinter Conference of Immunologists, Asilomar, CA 2000

Co-organizer, Keystone Symposium, Molecular and Cellular Biology of Leukocyte Regulatory Receptors, Lake Tahoe, CA 2002

Co-organizer, Keystone Symposium, NK and NKT Cell Biology, 2008

Faculty, FEBS International Summer School on Immunology, Ionian Village, Greece, 1998, 2000, 2002

Faculty, American Association of Immunologists Advanced Course in Immunology, 2000 - 2006

Experience:

Vice Chair, Department of Microbiology and Immunology, University of California San Francisco, 2003-present

Professor, Department of Microbiology and Immunology and the Cancer Research Institute, University of California San Francisco, 1999-present

Director, Department of Immunobiology, DNAX Research Institute for Molecular and Cellular Biology, 1997-1999

Associate Director, Department of Human Immunology, DNAX Research Institute for Molecular and Cellular Biology, 1993-1996

Senior Scientist, Department of Immunology, DNAX Research Institute for Molecular and Cellular Biology, Inc., 1991-1993

Becton Dickinson Research Fellow and Associate Research Director, Becton Dickinson Immunocytometry Systems, 1990-1991

Associate Research Director, Becton Dickinson Immunocytometry Systems, 1988-1991

Senior Research Scientist, Becton Dickinson Monoclonal Center, Inc., 1981-1988

Research Assistant Professor, Department of Pathology, University of New Mexico School of Medicine, 1981

Postdoctoral Fellow, supported by Damon Runyon-Walter Winchell Cancer Fund,
University of New Mexico School of Medicine, Department of Pathology, 1979-1981

Postdoctoral Fellow, supported by NIH Training Grant, University of North Carolina
Cancer Research Center at Chapel Hill, 1978-1979

University Teaching:

Microbiology 121 (UCSF) – Immunology for Pharmacists (Course organizer 2001)

Microbiology 208 (UCSF) – The Biology of Animal Viruses

Microbiology 204 (UCSF) – Advanced Graduate Immunology

Oral Biology 224 (UCSF) – Immunology for Dentistry Graduate Students

MI 206 (Stanford) - Animal Viruses - Principles of Virus Infection and Pathogenesis

MI212 (Stanford) – Advanced Immunology II

University Service:

UCSF Immunology Program, 1999- present

UCSF Immunology Program, Steering Committee, 2003-2006; Head 2006-

UCSF Biomedical Sciences, graduate training program, Member, 1999-present;
Executive Committee, 2005-present

UCSF Program in Biological Sciences, graduate training program, Member, 1999-
present; Executive Committee, 2005-present

UCSF Diabetes Center, Member, 2002-present

UCSF Liver Center, Member, 2002-present

UCSF Molecular Medicine Program, Member, 2002-present

UCSF Department of Microbiology & Immunology, Faculty Search Committee, Member,
2000

UCSF Department of Pathology, Faculty Search Committee, Member, 2000-2001

UCSF Sandler Chair of Asthma and Allergy Chair Search Committee, Member, 2000-2002

UCSF Cancer Research Center, Tumor Immunology Faculty Search Committee, Chair, 2001-2002

UCSF Cancer Center, Cancer & Immunity Program, Program Leader, 2000-present

UCSF Cancer Center, Hematological Malignancies Program, Member, 1999-present

UCSF Cancer Research Institute, Merit and Promotions Committee, Member, 2000-2005

UCSF Stewart Trust Cancer Research Award Review Committee, Member, 2001; Co-chair 2002

UCSF American Cancer Society Internal Grant Review Committee, Member, 2002; Chair, 2003-2005

UCSF Diabetes Center Faculty Search Committee, Member, 2002-2005

UCSF Department of Experimental Medicine, Faculty Search Committee, 2006-2007

Gladstone Institute, Faculty Search Committee, Member 2006-2007

Publications:

1. Lanier, L.L., M. Lynes, G. Haughton and P.J. Wettstein. 1978. Novel type of murine B cell lymphoma. *Nature* 271:554-555.
2. Babcock, G.F., L.L. Lanier, M.A. Lynes and G. Haughton. 1978. A simple method for the preparation of antisera specific for murine immunoglobulin heavy chains. *J. Immunol. Methods* 23:1-6.
3. Lynes, M.A., L.L. Lanier, G.F. Babcock and G. Haughton. 1978. Antigen-induced murine B cell lymphomas. I. Induction and characterization of CH1 and CH2. *J. Immunol.* 121:2352-2357.
4. Haughton, G., L.L. Lanier, G.F. Babcock and M.A. Lynes. 1978. Antigen- induced murine B cell lymphomas. II. Exploitation of the surface idiotype as tumor specific antigen. *J. Immunol.* 121:2358-2362.
5. Haughton, G., L.L. Lanier and G.F. Babcock. 1978. The murine kappa chain shift. *Nature* 275: 154-157.
6. Lanier, L.L. and G. Haughton. 1979. Tolerance to non H-2 histocompatibility antigens: Transplantation tolerance to the H-4 and H-7 histocompatibility antigens. *Transplantation* 27:208-211.
7. Lanier, L.L., G.F. Babcock, M.A. Lynes and G. Haughton. 1979. Early detection of the CH1 murine B cell lymphoma by tumor-associated idiotype in the serum. *Int. J. Cancer* 24:53-59.
8. Lanier, L.L., G. F. Babcock, M.A. Lynes and G. Haughton. 1979. Antigen-induced murine B cell lymphomas. III. Passive anti-idiotype antiserum immunotherapy and its combined effect with chemotherapy. *J. Natl. Cancer Inst.* 63:1417-1422.
9. Lanier, L.L., G. F. Babcock, R.B. Raybourne, L.W. Arnold, N.L. Warner and G. Haughton. 1980. Mechanism of B cell lymphoma immunotherapy with passive xenogeneic anti-idiotype serum. *J. Immunol.* 125:1730-1736.
10. Lanier, L.L. and N. L. Warner. 1981. Cell cycle related heterogeneity of Ia antigen expression on a murine B lymphoma cell line: Analysis by flow cytometry. *J. Immunol.* 126:626-631.
11. Lanier, L.L., N.L. Warner, L. W. Arnold, R.B. Raybourne and G. Haughton. 1981. B cell lymphomas in New Zealand and B10. H-2^aH-4^bp/Wts mice: Antigenic analysis by flow cytometry. In: *B lymphocytes in the immune response: Functional, developmental and interactive properties*. Developments in Immunology, Vol. 15. Eds. N. Klinman, D. Mosier, I. Scher and E. Vitetta, Elsevier North Holland, New York, p. 459-466.

12. Haughton, G., L.W. Arnold, L.L. Lanier, R.B. Raybourne and N.L. Warner. 1981. Induction of B cell lymphomas in B10.H-2^aH-4^bp/Wts mice. In: B lymphocytes in the immune response: Functional, developmental and interactive properties. Developments in Immunology, Vol. 15. Eds. N. Klinman, D. Mosier. I. Scher and E. Vitetta, Elsevier North Holland, New York, p. 455-458.
13. Lanier, L.L., N.L. Warner, J.A. Ledbetter and L.A. Herzenberg. 1981. Expression of Lyt-1 antigen on certain murine B cell lymphomas. J. Exp. Med. 153:998-1003.
14. Lanier, L.L. and N.L. Warner, J.A. Ledbetter and L.A. Herzenberg. 1981. Quantitative immunofluorescent analysis of surface phenotypes of murine B cell lymphomas and plasmacytomas with monoclonal antibodies. J. Immunol. 127:1691-1697.
15. Lanier, L.L. and N.L. Warner. 1981. Paraformaldehyde fixation of hematopoietic cells for quantitative flow cytometry (FACS) analysis. J. Immunol. Methods 47:25-30.
16. Warner, N.L., R.K. Cheney, L.L. Lanier, M.J. Daley and E. B. Walker. 1982. Differentiation heterogeneity in murine hematopoietic tumors. In: Maturation factors and cancer. Prog. Cancer Res. Therapy, Vol. 23. Ed. M.A.S. Moore, Raven Press, New York, p. 223-243.
17. Lanier, L.L., G.A. Gutman, D.E. Lewis, S.T. Griswold and N.L. Warner. 1982. Monoclonal antibodies against rat immunoglobulin kappa chains. Hybridoma 1:125-131.
18. Walker, E.B., L.L. Lanier and N.L. Warner. 1982. Characterization and functional properties of B lymphoma and macrophage tumor cell lines in accessory cell replacement assays. J. Immunol. 128:852-859.
19. Lanier, L.L. and N.L. Warner. 1982. Lym 7.2: Monoclonal antibody defining an alloantigen similar or identical to Ly 7.2. Hybridoma 1:227-241.
20. Walker, E.B., L.L. Lanier and N.L. Warner. 1982. Concomitant induction of the cell surface expression of Ia determinants and accessory cell function by a murine macrophage tumor cell line. J. Exp. Med. 155:629-634.
21. Lanier, L.L. and N.L. Warner. 1982. Activation of murine B lymphomas. In: B and T cell tumors. UCLA Symposium of Molecular and Cellular Biology, Vol. 24. Ed. E. Vitetta. Academic Press, New York, p. 431-443.
22. Lanier, L.L., E.B. Walker, E.R. Richie and N.L. Warner. 1982. Murine hematopoietic cell tumors: Models for analysis of cellular differentiation. In: B and T cell tumors. UCLA Symposium on Molecular and Cellular Biology, Vol. 24. Ed. E. S. Vitetta, Academic Press, New York, p.29-42.
23. Lee, J.C., L.L. Lanier, A.J. Hapel and J.N. Ihle. 1982. Production of interleukin-3 by murine tumor cells. In: B and T cell tumors. UCLA Symposium on Molecular and Cellular Biology, Vol. 24. Ed. E. S. Vitetta. Academic Press, New York, p.425-430.

24. Lanier, L.L. 1982. Activation of murine B cell lymphomas. I. Influence of lipopolysaccharide. *J. Immunol.* 129:1130-1137.
25. Lanier, L.L., L.W. Arnold, R.B. Raybourne, S. Russell, M.A. Lynes, N.L. Warner and G. Haughton. 1982. Transplantable B cell lymphomas in B10.H- 2^aH-4^bp/Wts mice. *Immunogenetics* 16:367-371.
26. Lanier, L.L. and N.L. Warner. 1983. Lym 7.3: New murine specificity defining third allele of the Ly 7 locus. *Hybridoma* 2:177-185.
27. Lanier, L.L., E.G. Engleman, P. Gatenby, G.F. Babcock, N.L. Warner and L.A. Herzenberg. 1983. Correlation of functional properties of human lymphoid cell subsets and surface marker phenotypes using multiparameter analysis and flow cytometry. *Immunol. Rev.* 74:143-160.
28. Lanier, L.L., E. Richie, A. Howell and J. Allison. 1983. Expression of Ly-1 and Ly-2 on a spontaneous AKR B cell lymphoma. *Immunogenetics* 17:655-659.
29. Lanier, L.L., A.M. Le. J.H. Phillips, N.L. Warner and G.F. Babcock. 1983. Subpopulations of human natural killer cells defined by expression of the Leu 7 (HNK-1) and Leu 11 (NK-15) antigens. *J. Immunol.* 131:1789-1796.
30. Warner, N.L., L.L. Lanier, E.B. Walker, C.C. Stewart, G. Wood and C. Balch. 1983. Hematopoietic tumors: Normal or abnormal models of leukocyte differentiation? In: *Hybridomas and Cellular Immortality*. Eds. B. Tom and J. Allison. Plenum Press, New York, p. 27-44.
31. Lanier, L.L., J.H. Phillips, N.L. Warner and G.F. Babcock. 1984. A human natural killer cell-associated antigen defined by monoclonal antibody anti-Leu 11 (NKP-15): Functional and two-color flow cytometry analysis. *J. Leukoc. Biol.* 35:11-17.
32. Warner, N.L., L.L. Lanier, A. Jackson, G. Babcock and R. Evans. 1984. Multiparameter approaches to FACS analysis of human leukocyte cell surface antigens. In: *Human leukocyte markers detected by monoclonal antibodies*. Eds. A. Bernard, L. Boumsell, J. Dausset, C. Milstein and S. Schlossman. Springer-Verlag, New York, p. 621-630.
33. Loken, M.R. and L.L. Lanier. 1984. Three color immunofluorescence analysis of Leu antigens on human peripheral blood using two lasers on a Fluorescence Activated Cell Sorter. *Cytometry* 5:151-158.
34. Lanier, L.L. and M.R. Loken. 1984. Human lymphocyte subpopulations identified using three-color immunofluorescence and flow cytometry: Correlation of Leu 2, Leu 3, Leu 7, Leu 8 and Leu 11 cell surface antigen expression. *J. Immunol.* 132:151-156.

35. Phillips, J.H., A.M. Le and L.L. Lanier. 1984. Natural killer cells activated in a human mixed lymphocyte response culture identified by expression of Leu 11 and class II histocompatibility antigens. *J. Exp. Med.* 159:993-1008.
36. Perussia, B., G. Trinchieri, A. Jackson, N.L. Warner, J. Faust, H. Rumpold, D. Kraft and L.L. Lanier. 1984. The Fc receptor for IgG on human natural killer cells: Phenotypic, functional and comparative studies with monoclonal antibodies. *J. Immunol.* 133: 180-189.
37. Parks, D.R., L.L. Lanier and L.A. Herzenberg. 1986. Flow cytometry and fluorescence-activated cell sorting. In: *Handbook of experimental immunology*, 4th ed., Eds. D.M. Weir, L.A. Herzenberg, C.C. Blackwell, and L.A. Herzenberg, Blackwell Scientific Publications, Oxford, UK. Chapter 29.
38. Chen, Y.X., R. Evans, M.S. Pollack. L.L. Lanier, J.H. Phillips, C. Rousso, N.L. Warner and F.M. Brodsky. 1984. Characterization and expression of the HLA- DC antigens defined by anti-Leu 10 antigen. *Hum. Immunol.* 10:221-235.
39. Basham, T., W. Smith, L. Lanier, V. Morhenn and T. Merigan. 1984. Regulation of expression of class II major histocompatibility antigens on human peripheral blood monocytes and Langerhans cells by interferon. *Hum. Immunol.* 10:83-93.
40. Phillips, J.H., N.L. Warner and L.L. Lanier. 1984. Correlation of biophysical properties and cell surface antigenic profile of Percoll gradient separated natural killer cells. *Nat. Immun. Cell Growth Regul.* 3:73-86.
41. Allison, J.P., L. Ridge, J. Lund, J. Gross-Pelose, L. Lanier and B.W. McIntyre. 1984. The murine T cell antigen receptor and associated structures. *Immunol. Rev.* 81:145-160.
42. Lanier, L.L., J.H. Phillips and N.L. Warner. 1986. Monoclonal antibodies to human lymphocytes. In: *Methods in Haematology*, Ed. P. Beverley, Chapter 9.
43. Allison, J.P., B.W. McIntyre, F.C-Y. Cheung and L.L. Lanier. 1984. Molecular characterization of the murine T cell antigen receptor In: *Regulation of the Immune Response*, Eds. H. Cantor, L. Chess and E. Sercarz, Alan R. Liss, Inc., NY, p.389-398.
44. Hogarth, P.M., I.F.C. McKenzie, L. Lanier, D.W. Bailey and B.A. Taylor. 1984. Location of Ly-7 on mouse chromosome 12. *Immunogenetics* 19:539-543.
45. Lanier, L.L., C.J. Benike, J.H. Phillips and E.G. Engleman. 1985. Recombinant interleukin-2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. *J. Immunol.* 134:794-801.
46. Allison, J.P. and L.L. Lanier. 1985. Identification of antigen receptor-associated structures on murine T cells. *Nature* 314:107-109.

47. Lanier, L.L. and J.H. Phillips. 1986. A map of the cell surface antigens expressed on resting and activated human natural killer cells. In: *Leukocyte Typing II*, Eds. E.L. Reinherz, B.F. Haynes, L.M. Nadler and I.D. Bernstein, Springer-Verlag, New York, p. 157-170.
48. Phillips, J.H. and L.L. Lanier. 1985. K562 tumor cells preferentially activate Leu 11⁺ human large granular lymphocytes in a mixed lymphocyte response culture. In: *Mechanisms for Cytotoxicity by NK Cells*. Eds. R.B. Herberman and D.M. Callewaert, Academic Press, NY, p. 563-587.
49. Allison, J.P., B.W. McIntyre, L.L. Ridge, J. Gross-Pelose and L.L. Lanier. 1985. Molecular characterization of the murine T cell antigen receptor and associated structures. *Federation Proc.* 44:2870-2873.
50. Waldor, M.K., R. Hardy, L.A. Herzenberg, L.A. Herzenberg, L.L. Lanier, S. Sriram, M. Lim and L. Steinman. 1985. Reversal of experimental allergic encephalomyelitis with a monoclonal antibody to a T-cell subset marker (L3T4). *Science* 227:415-417.
51. Lanier, L.L. 1985. Lymphocyte surface antigens. *Federation Proc.* 44:2863-2864.
52. H.E. Prince, K. Hirji, L.S. Waldbeser, S. Plaeger-Marshall, S. Kleinman and L.L. Lanier. 1985. Influence of racial background on the distribution of T cell subsets and Leu 11 positive lymphocytes in healthy blood donors. *Diagn. Immunol.* 3:33-37.
53. Green, P.L., W.W. Lamph, J. Dudley, A. Arfsten, R. Risser, L.L. Lanier, N.L. Warner, J-S. Tung and M.P. Scheid. 1985. Phenotypic variation in clonal Abelson virus lymphoma cells. *J. Immunol.* 134:1268-1275.
54. Phillips, J.H. and L.L. Lanier. 1985. A model for the differentiation of human natural killer cells: Studies on the in vitro activation of Leu 11⁺ granular lymphocytes with a NK-sensitive tumor cell, K562. *J. Exp. Med.* 161:1464-1482.
55. Lanier, L.L., M.A. Arnaout, R. Schwarting, N.L. Warner and G.D. Ross. 1985. p150/95, Third member of the LFA-1/CR3 polypeptide family identified by anti-Leu M5 monoclonal antibody. *Eur. J. Immunol.* 15:713-718.
56. Fox, R.I., T.E. Hugli, L. Lanier and E.L. Morgan. 1985. Salivary gland lymphocytes in primary Sjogren's syndrome lack lymphocyte subsets defined by monoclonal antibodies Leu 7 and Leu-11 antigens. *J. Immunol.* 135:207-214.
57. Loken, M.R., L.L. Lanier, D. Recktenwald and N.L. Warner. 1984. Flow cytometry monitoring leukocyte sets and subsets. In: *Quo Vadis? Flow Cytometry and Monoclonal Antibodies for Therapy Monitoring*. Ed. P. Gros, F.K. Jansen, P. Poncelet and R. Roncucci, Sanofi Recherche, Montpellier, France, p. 107-118.
58. Sriram, S. and L. Lanier. 1986. NK cell function in a patient with IgM monoclonal antibody against myelin associated glycoprotein. *Neurology* 36:566-568.

59. Phillips, J.H. and L.L. Lanier. 1986. Lectin-dependent and anti-CD3 induced cytotoxicity are preferentially mediated by peripheral blood cytotoxic T lymphocytes expressing Leu-7 antigen. *J. Immunol.* 136:1579-1585.
60. Lanier, L.L., T.J. Kipps and J.H. Phillips. 1985. Functional properties of a unique subset of cytotoxic CD3⁺ T lymphocytes that express Fc receptors for IgG (CD16/Leu 11 antigen). *J. Exp. Med.* 162:2089-2106.
61. Lanier, L.L., S. Cwirla, N. Federspiel and J.H. Phillips. 1986. Human natural killer cells isolated from peripheral blood do not rearrange T cell antigen receptor β -chain genes. *J. Exp. Med.* 163:209-214.
62. Krensky, A.M., L.L. Lanier and E.G. Engleman. 1985. Lymphocyte subsets and surface molecules in man. *Clin. Immunol. Rev.* 4:95-138.
63. Clayberger, C., B. Dyer, B. McIntyre, T.D. Koller, B. Hardy, P. Parham, L.L. Lanier and A.M. Krensky. 1986. Function and cell distribution of KC-1, a novel natural killer cell associated antigen. *J. Immunol.* 136:1537-1541.
64. Lanier, L.L. and J.H. Phillips. 1986. Evidence for three types of human cytotoxic lymphocyte. *Immunol. Today* 7:132-134.
65. Lanier, L.L., and J.H. Phillips. 1986. A schema for the classification of human cytotoxic lymphocytes based on T-cell antigen receptor gene rearrangement and Fc receptor (CD16) or Leu 19/NKH-1 antigen expression. In: *Proceedings of the International Symposium on Natural Immunity*, Eds. R.B. Herberman, et al., Krager, New York.
66. Lanier, L.L., A.M. Le, C.I. Civin, M.R. Loken and J.H. Phillips. 1986. The relationship of CD16 (Leu 11) and Leu 19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. *J. Immunol.* 136:4480-4486.
67. Lanier, L.L., J.J. Ruitenberg and J.H. Phillips. 1986. Human CD3⁺ T lymphocytes that express neither CD4 nor CD8 antigens. *J. Exp. Med.* 164:339-344.
68. Freimark, B., L. Lanier, J. Phillips, T. Quertermous and R. Fox. 1987. Comparison of T cell receptor gene rearrangements in patients with large granular T cell leukemia and Felty's syndrome. *J. Immunol.* 138:1724-1729.
69. McIntyre, B., L.L. Lanier and J.P. Allison. 1986. The murine T cell receptor. In: *Antigen-specific T-cell receptors and factors*, Ed. J.J. Marchalonis, CRC Press, Boca Raton, FL, Chapter 2.
70. Lanier, L.L., J.P. Allison and J.H. Phillips. 1986. Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: Implications for differentiation. *J. Immunol.* 137:2501-2507.

71. Lanier, L.L., J.J. Ruitenberg, J.P. Allison and A. Weiss. 1986. Distinct epitopes on the T cell antigen receptor of HPB-ALL tumor cells identified by monoclonal antibodies. *J. Immunol.* 137:2286-2292.
72. Phillips, J.H. and L.L. Lanier. 1986. Dissection of the lymphokine activated killer phenomenon: Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytotoxicity. *J. Exp. Med.* 164:814-825.
73. Lanier, L.L., A.M. Le, S. Cwirla, N. Federspiel and J.H. Phillips. 1986. Antigenic, functional and molecular genetic studies on human natural killer cells and cytotoxic T lymphocytes not restricted by the major histocompatibility complex. *Federation Proc.* 45:2823-2828.
74. Lanier, L.L., S. Cwirla and J.H. Phillips. 1986. Genomic organization of T-cell receptor gamma genes in human peripheral blood natural killer cells. *J. Immunol.* 137:3375-3377.
75. Tarkkanen, J., E. Saksela and L.L. Lanier. 1986. Bacterial activation of human natural killer cells: Characteristics of the activation process and identification of the effector cell. *J. Immunol.* 137:2428-2433.
76. Lanier, L.L., J.H. Phillips, J. Hackett, Jr., M. Tutt and V. Kumar. 1986. Natural killer cells: Definition of a cell type rather than a function. *J. Immunol.* 137:2735-2739.
77. Lanier, L.L. and J.H. Phillips. 1986. Human thymic and peripheral blood non- MHC-restricted cytotoxic lymphocytes. *Med. Oncol. & Tumor Pharmacother.* 3:247-254.
78. Lanier, L.L., A.T. Serafini, J.J. Ruitenberg, S. Cwirla, N.A. Federspiel, J.H. Phillips, J.P. Allison and A. Weiss. 1987. The gamma T cell antigen receptor. *J. Clin. Immunol.* 7:429-440.
79. Allison, J.P. and L.L. Lanier. 1987. The T cell antigen receptor gamma gene: Rearrangement and cell lineages. *Immunol. Today* 8:293-296.
80. Nagasawa, R., Gross, O. Kanagawa, K. Townsend, L.L. Lanier, J. Chiller and J.P. Allison. 1987. Identification of a novel T cell surface disulfide-bonded dimer distinct from the α/β antigen receptor. *J. Immunol.* 138:815-824.
81. Lanier, L.L. and A. Weiss. 1986. Presence of Ti (WT31) negative T lymphocytes in normal blood and thymus. *Nature* 324:268-270.
82. Allison, J.P. and L.L. Lanier. 1987. Structure, function and serology of the T cell antigen receptor complex. *Ann. Rev. Immunol.* 5:503-540.
83. Lanier, L.L., A.M. Le, A.H. Ding, E.L. Evans, A.M. Krensky, C. Clayberger and J.H. Phillips. 1987. Expression of Leu-19 (NKH-1) antigen on IL-2 dependent cytotoxic and non-cytotoxic T cell lines. *J. Immunol.* 138:2019-2023.

84. Lanier, L.L., A.M. Le, A.H. Ding and E.L. Evans. 1987. Analysis of the workshop T-cell monoclonal antibodies by "indirect two-color immunofluorescence" and multiparameter flow cytometry. In: Leukocyte Typing III, Eds. A. McMichael et al., Oxford University Press, UK, p. 62-68.
85. Lanier, L.L., J.J. Ruitenberg, J.P. Allison and A. Weiss. 1987. Biochemical and flow cytometric analysis of CD3 and Ti expression on normal and malignant T cells. In: Leukocyte Typing III, Eds. A. McMichael et al., Oxford University Press, UK, p. 175-178.
86. Phillips, J.H., B.T. Gemlo, W.W. Myers, A.A. Rayner and L.L. Lanier. 1988. The contribution of NK and T-cells to the lymphokine activated killer cell phenomenon. In: Cytolytic lymphocyte clones and complement as effectors of the immune system, Vol. II, Ed. E.R. Podack, CRC Press, Boca Raton, FL, pp. 193-204.
87. Lanier, L.L., N.A. Federspiel, J.J. Ruitenberg, J.H. Phillips, J.P. Allison, D. Littman and A. Weiss. 1987. The T cell antigen receptor complex expressed on normal peripheral blood CD4⁺, CD8⁻ T lymphocytes: A CD3-associated disulfide-linked γ -chain heterodimer. *J. Exp. Med.* 165:1076-1094.
88. Phillips, J.H. and L.L. Lanier. 1987. Acquisition of non-MHC restricted cytotoxic function by IL-2 activated thymocytes with an "immature" antigenic phenotype. *J. Immunol.* 139:683-687.
89. Weiss, A., P.F. Dazin, R. Shields, S.M. Fu and L.L. Lanier. 1987. Functional competency of T cell antigen receptors in human thymus. *J. Immunol.* 139:3245-3250.
90. Phillips, J.H., B.T. Gemlo, W.W. Myers, A.A. Rayner and L.L. Lanier. 1987. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. *J. Clin. Oncol.* 5:1933-1941.
91. Herberman, R.B., J. Hiserodt, N. Vujanovic, C. Balch, E. Lotzova, R. Bolhuis, S. Golub, L.L. Lanier, J.H. Phillips, C. Riccardi, J. Ritz, A. Santoni, R.E. Schmidt and A. Uchida. 1987. Lymphokine-activated killer cell activity: Characteristics of effector cells and their progenitors in blood and spleen. *Immunol. Today* 8:178-181.
92. Phillips, J.H., A. Weiss, B.T. Gemlo, A.A. Rayner and L.L. Lanier. 1987. Evidence that the T cell antigen receptor may not be involved in cytotoxicity mediated by γ/δ and α/β thymic cell lines. *J. Exp. Med.* 166:1579-1584.
93. Loh, E., L.L. Lanier, C.W. Turck, D.R. Littman, M.M. Davis, Y-H. Chien and A. Weiss. 1987. Identification and sequence of the fourth human T cell receptor chain. *Nature* 330:569-572.
94. Richie, E.R., B. McIntyre, N. Crispe, J. Kimura, L.L. Lanier and J.P. Allison. 1988. α/β T-cell antigen receptor gene and protein expression occurs at early stages of thymocyte differentiation. *Proc. Natl. Acad. Sci. U.S.A.* 85:1174-1178.

95. Lanier, L.L. and J.H. Phillips. 1988. What are natural killer cells? ISI Atlas of Science: Immunology. Philadelphia, PA, vol. 1, pp. 15.
96. Nagler, A., P. Greenberg, L.L. Lanier and J.H. Phillips. 1988. The effect of recombinant interleukin 2-activated natural killer cells on autologous peripheral blood hematopoietic progenitors. *J. Exp. Med.* 168:47-54.
97. Lanier, L.L., D.W. Buck, L. Rhodes, A. Ding, E. Evans, C. Barney and J.H. Phillips. 1988. Interleukin-2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu 23 activation antigen. *J. Exp. Med.* 167:1572-1585.
98. Nagler, A., L.L. Lanier and J.H. Phillips. 1988. The effects of IL-4 on human natural killer cells: A potent regulator of IL-2 activation and proliferation. *J. Immunol.* 141:2349-2351.
99. Skettino, S., J.H. Phillips, L.L. Lanier, A. Nagler and P.L. Greenberg. 1988. Selective generation of erythroid burst promoting activity by recombinant interleukin-2-stimulated human T lymphocytes and natural killer cells. *Blood* 71:907-914.
100. Lanier, L.L., J.J. Ruitenberg and J.H. Phillips. 1988. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. *J. Immunol.* 141:3478-3485.
101. Lanier, L.L. 1988. Killer cells: An offensive defense. *The Scientist* 2:15.
102. Testi, R., J.H. Phillips and L.L. Lanier. 1988. Constitutive expression of a phosphorylated activation antigen (Leu 23) by CD3bright human thymocytes. *J. Immunol.* 141:2557-2563.
103. Lanier, L.L. and J.H. Phillips. 1988. Effectors, repertoire and receptors involved in lymphocyte-mediated MHC-unrestricted cytotoxicity. *Annales d'Immunologie* 139:450-456.
104. Loh, E.Y., S. Cwirla, A.T. Serafini, J.H. Phillips, and L.L. Lanier. 1988. Human T-cell receptor delta chain: Genomic organization, diversity and expression in populations of cells. *Proc. Natl. Acad. Sci. USA* 85:9714-9718.
105. Lanier, L.L., J.J. Ruitenberg, R.L.H. Bolhuis, J. Borst, J.H. Phillips and R. Testi. 1988. Structural and serological heterogeneity of γ/δ T cell antigen receptor expression in thymus and peripheral blood. *Eur. J. Immunol.* 18:1985-1992.
106. Groh, V., S. Porcelli, M. Fabbi, L.L. Lanier, L.J. Picker, T. Anderson, R.A. Warnke, A.K. Bhan, J.L. Strominger, and M.B. Brenner. 1989. Human lymphocytes bearing TCR γ/δ are phenotypically diverse and evenly distributed throughout the lymphoid system. *J. Exp. Med.* 169:1277-1294.
107. Testi, R., J.H. Phillips and L.L. Lanier. 1989. Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering: Requirement for receptor crosslinking, prolonged elevation of intracellular $[Ca^{++}]$ and stimulation of protein kinase C. *J. Immunol.* 142:1854-1860.

108. Loh, E.Y., J.F. Elliott, S. Cwirla, L.L. Lanier and M.M. Davis. 1989. Polymerase chain reaction with single-sided specificity: Analysis of T cell receptor δ chain. *Science* 243:217-220.
109. Testi, R. and L.L. Lanier. 1989. Functional expression of CD28 on T cell antigen receptor γ/δ -bearing T lymphocytes. *Eur. J. Immunol.* 19:185-188.
110. Lanier, L.L., J.H. Phillips and R. Testi. 1989. Membrane anchoring and spontaneous release of CD16 (FcR III) by natural killer cells and granulocytes. *Eur. J. Immunol.* 19:775-778.
111. Lanier, L.L., R. Testi, J. Bindl and J.H. Phillips. 1989. Identity of Leu 19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule (N-CAM). *J. Exp. Med.* 169:2233-2238.
112. Lanier, L.L. and J.H. Phillips. 1990. NK Cells: Membranes structures triggering cell-mediated cytotoxicity. In: *Leucocyte Typing IV*, Eds. W. Knapp et al., Oxford University Press, UK, p. 1064-1068.
113. Brenner, M.B., V. Groh, S.A. Porcelli, F. Hochstenbach, H. Band, L.L. Lanier, J. McLean and M.S. Krangel. 1990. Structure and distribution of the human $\gamma\delta$ T cell receptor. In: *Leucocyte Typing IV*, Ed. W. Knapp et al., Oxford University Press, UK, p. 1049-1053.
114. Arnaout, M.A., L.L. Lanier and D.V. Faller. 1988. Relative contribution of the leukocyte molecules Mo1, LFA-1 and p150,95 (LeuM5) in adhesion of granulocytes and monocytes to vascular endothelium is tissue and stimulus-specific. *J. Cell. Physiol.* 137:305-309.
115. Lanier, L.L. 1991. Cells of the immune response: Lymphocytes and mononuclear phagocytes. In: *Basic & Human Immunology*. 7th ed., Eds. D.P. Stites and A.I. Terr, Appleton & Lange, San Mateo, CA, p.61-72.
116. Testi, R., J.H. Phillips and L.L. Lanier. 1989. T cell activation via Leu 23 (CD69). *J. Immunol.* 143:1123-1128.
117. Phillips, J.H., T. Takeshita, K. Sugamura and L.L. Lanier. 1989. Activation of natural killer cells via the p75 interleukin 2 receptor. *J. Exp. Med.* 170:291-296.
118. Clark, E.A. and L.L. Lanier. 1989. Report from Vienna: In search of all surface molecules expressed on human leukocytes. *J. Clin. Immunol.* 9:265.
119. Nagler, A., L.L. Lanier, S. Cwirla and J.H. Phillips. 1989. Comparative studies of human FcRIII positive and negative natural killer cells. *J. Immunol.* 143:3183-3191.
120. Lanier, L.L., S. Cwirla, G. Yu, R. Testi and J.H. Phillips. 1989. Membrane anchoring of a human IgG Fc receptor (CD16) determined by a single amino acid. *Science* 246:1611-1613.

121. Lanier, L.L., G. Yu and J.H. Phillips. 1989. Co-association of CD3 ζ with receptor (CD16) for IgG on human natural killer cells. *Nature* 342:803-805.
122. Nagler, A., L.L. Lanier and J.H. Phillips. 1990. Constitutive expression of high affinity interleukin 2 receptors on human CD16- natural killer cells in vivo. *J. Exp. Med.* 171:1527-1533.
123. Lanier, L.L., G. Yu and J.H. Phillips. 1991. Analysis of Fc γ RIII (CD16) membrane expression and association with CD3 ζ and Fc ϵ RI- γ by site-directed mutation. *J. Immunol.* 146:1571-1576.
124. Phillips, J.H., C. Chang and L.L. Lanier. 1991. Platelet-induced expression of Fc γ RIII (CD16) on human monocytes. *Eur. J. Immunol.* 21:895-899.
125. Lanier, L.L. and A.L. Jackson. 1992. Differentiation antigens expressed on leukocytes: Immune cell phenotyping by flow cytometry. In: *Manual of Clinical Laboratory Immunology*, 4th Ed., Eds. N. Rose, et al., ASM Press, Washington, D.C., p. 157-163.
126. Lanier, L.L., C. Chang, M. Azuma, J. Ruitenberg, J. Hemperly and J.H. Phillips. 1991. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). *J. Immunol.* 146:4421-4426.
127. Lanier, L.L. and D. Recktenwald. 1991. Multi-color immunofluorescence and flow cytometry. *Methods: A Companion to Methods in Enzymology* 2:192-199.
128. Lanier, L.L. 1992. Flow cytometry reveals the complexity and diversity of the human immune system. In: *Flow Cytometry: Principles and Clinical Applications*, Eds. K. Bauer, R.E. Duque and T.V. Shankey, Williams and Wilkins, Baltimore, MD, Chapter 4, p. 63-70.
129. Phillips, J.H., A. Nagler, H. Spits and L.L. Lanier. 1992. Immunomodulating effects of IL-4 on human natural killer cells. In: *Interleukin-4: Structure and Function*, Ed. H. Spits, CRC Press, Boca Raton, FL, Chapter 11.
130. Azuma, M., M. Cayabyab, D. Buck, J.H. Phillips and L.L. Lanier. 1992. CD28 interaction with B7 co-stimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes, *J. Exp. Med.* 175:353-360.
131. Harrison, D.H., J.H. Phillips and L.L. Lanier. 1991. Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated Fc γ RIII (CD16-II), *J. Immunol.* 147:3459-3465.
132. Phillips, J.H., L. McKinney, M. Azuma, H. Spits and L.L. Lanier. 1991. A novel β 4, α 6 integrin-associated epithelial cell antigen involved in natural killer cell and antigen-specific cytotoxic T lymphocyte cytotoxicity. *J. Exp. Med.* 174:1571-1581.
133. Lanier, L.L. and J.H. Phillips. 1992. Natural killer cells. *Curr. Opin. Immunol.* 4:38-42.

134. Phillips, J.H., T. Hori, A. Nagler, N. Bhat, H. Spits and L.L. Lanier, 1992. Ontogeny of human natural killer cells: Fetal NK cells mediate cytolytic function and express cytoplasmic CD3 ϵ , δ proteins. *J. Exp. Med.* 175:1055-1066.
135. Lanier, L.L., C. Chang, H. Spits and J.H. Phillips. 1992. Expression of cytoplasmic CD3 ϵ proteins in activated human adult NK cells and CD3 γ , δ , ϵ complexes in fetal NK cells: Implications for the relationship of NK and T lymphocytes. *J. Immunol.* 149:1876-1880.
136. Lanier, L.L. and J.H. Phillips. 1993. Triggering structures on NK cells. In: *Cytotoxic Cells: Recognition, Effector Function, Generation and Methods*, ed., M. Sitkovsky and P. Henkart, Birkhauser Press, Boston, MA, pp. 84-95.
137. Azuma, M., M. Cayabyab, D. Buck, J.H. Phillips and L.L. Lanier. 1992. Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. *J. Immunol.* 149:1115-1123.
138. Hori, T., J.H. Phillips, B. Duncan, L.L. Lanier and H. Spits. 1992. Human fetal liver-derived CD7⁺CD2^{low}CD3⁺CD56⁻ clones that express CD3 γ , δ and ϵ and proliferate in response to IL-2, IL-3, IL-4, or IL-7: Implications for the relationship to T and NK cells. *Blood* 80:1270-1278.
139. Lanier, L.L., H. Spits and J.H. Phillips. 1992. The developmental relationship between NK cells and T cells. *Immunol. Today* 13:392-395.
140. Azuma, M., J.H. Phillips and L.L. Lanier. 1992. CD28 co-stimulation of T cell-mediated cytotoxicity. *Int. J. Cancer, Supplement* 7, pp. 33-35.
141. Azuma, M., M. Cayabyab, J.H. Phillips and L.L. Lanier. 1993. Requirements for CD28-dependent T cell-mediated cytotoxicity. *J. Immunol.* 150:2091-2101.
142. Lanier, L.L. 1993. Distribution and function of lymphocyte surface antigens: Molecules co-stimulating T lymphocyte activation and effector function. *Annals New York Academy of Sciences* 677:86-91.
143. Azuma, M., J.H. Phillips and L.L. Lanier. 1993. CD28⁻ T lymphocytes: Antigenic and functional properties. *J. Immunol.* 150:1147-1159.
144. Azuma, M., H. Yssel, J.H. Phillips, H. Spits and L.L. Lanier. 1993. Functional expression of B/BB1 on activated T lymphocytes. *J. Exp. Med.* 177:845-850.
145. M. Cayabyab, J.H. Phillips and L.L. Lanier. 1994. CD40 preferentially costimulates activation of CD4⁺ T lymphocytes. *J. Immunol.* 152:1523-1531.
146. Litwin, V., J. Gumperz, P. Parham, J.H. Phillips and L.L. Lanier. 1993. Specificity of HLA class I antigen recognition by human NK clones: Evidence for clonal heterogeneity,

- protection by self and non-self alleles and influence of the target cell type. *J. Exp. Med.* 178:1321-1336.
147. Yssel, H., P. Schneider and L.L. Lanier. 1993. Interleukin-7 induces the B7/BB1 antigen on human cord blood and peripheral blood T cells and T cell clones. *Int. Immunol.* 5:753-759.
 148. Sanchez, M.J., H. Spits, L.L. Lanier and J.H. Phillips. 1993. Human natural killer cell committed thymocytes and their relationship to the T cell lineage. *J. Exp. Med.* 178:1857-1866.
 149. Sanchez, M.J., M. Muench, M. -G. Roncarolo, L.L. Lanier and J.H. Phillips. 1994. Identification of a common T/natural killer cell progenitor in human fetal thymus. *J. Exp. Med.* 180:569-576.
 150. Azuma, M., D. Ito, H. Yagita, K. Okumura, J.H. Phillips, L.L. Lanier and C. Somoza. 1993. B70 antigen is a second ligand for CTLA-4 and CD28. *Nature* 366:76-79.
 151. Murphy, E.E, G. Terres, S.E. Macatonia, C-S. Hsieh, J. Mattson, L.L. Lanier, M. Wysocka, G. Trinchieri, K. Murphy and A. O'Garra. 1994. B7 and Interleukin-12 cooperate for proliferation and interferon γ production by mouse T helper clones that are unresponsive to B7 costimulation. *J. Exp. Med.* 180:223-231.
 152. Lanier, L.L. and J.J. Hemperly. 1995. NK3: CD56 and CD57 Cluster Workshop Report. In: *Leukocyte Typing V: White cell differentiation antigens*. Ed. S. Schlossman, L. Boumsell, W. Gilks, J. Harlan, T. Kishimoto, C. Morimoto, J. Ritz, S. Shaw, R. Silverstein, T. Springer, T. Tedder and R. Todd. Oxford University Press, p.1398-1400.
 153. Ritz, J., G. Trinchieri and L.L. Lanier. 1995. NK1 NK-cell antigens: section report. In: *Leukocyte Typing V: White cell differentiation antigens*. Ed. S. Schlossman, L. Boumsell, W. Gilks, J. Harlan, T. Kishimoto, C. Morimoto, J. Ritz, S. Shaw, R. Silverstein, T. Springer, T. Tedder and R. Todd. Oxford University Press, p.1367-1372.
 154. Cifone, M.G., R. De Maria, P. Roncaioli, M.R. Rippo, M. Azuma, L.L. Lanier, A. Santoni and R. Testi. 1994. Apoptotic signaling through CD95 (FAS/APO-1) activates an acidic sphingomyelinase. *J. Exp. Med.* 180:1547-1552.
 155. Litwin, V., J. Gumperz, P. Parham, J.H. Phillips and L.L. Lanier. 1994. NKB1: Natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. *J. Exp. Med.* 180:537-543.
 156. Lanier, L.L., C. Chang and J.H. Phillips. 1994. Human NKR-P1A: A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. *J. Immunol.* 153:2417-2428.
 157. Lanier, L.L., S. O'Fallon, C. Somoza, J.H. Phillips, P.S. Linsley, K. Okumura, D. Ito, M. Azuma 1995. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production and generation of CTL. *J. Immunol.* 154:97-105.

158. Azuma, M. and L.L. Lanier. 1995. The role of CD28 costimulation in the generation of cytotoxic T lymphocytes. *Current Topics in Microbiology and Immunology* 198:59-74.
159. Gumperz, J.E., V. Litwin, J.H. Phillips, L.L. Lanier and P. Parham. 1995. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. *J. Exp. Med.* 181:1133-1144.
160. Lanier, L.L. and J.H. Phillips. 1995. NK cell recognition of major histocompatibility complex class I molecules. *Semin. Immunol.* 7:75-82.
161. Caux, C., B. Vanbervliet, C. Massacrier, M. Azuma, K. Okumura, L.L. Lanier and J. Banchereau. 1994. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. *J. Exp. Med.* 180:1841-1847.
162. Phillips, J.H., J. Gumperz, P. Parham and L.L. Lanier. 1995. Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. *Science* 268:403-405.
163. Lanier, L.L., J. Gumperz, P. Parham, I. Melero, M. López-Botet and J.H. Phillips. 1995. The NKB1 and HP-3E4 NK cell receptors are structurally distinct glycoproteins and independently recognize polymorphic HLA-B and HLA-C molecules. *J. Immunol.* 154:3320-3327.
164. Warren, H.S., B.F. Kinnear, J.H. Phillips and L.L. Lanier. 1995. Production of IL-5 by human NK cells and regulation of IL-5 secretion by IL-4, IL-10 and IL-12. *J. Immunol.* 154:5144-5152.
165. Spits, H., L.L. Lanier and J.H. Phillips. 1995. Development of human T and natural killer cells. *Blood* 85:2654-2670.
166. Somoza, C. and L.L. Lanier. 1995. T cell costimulation via CD28-CD80/CD86 and CD40-CD40 ligand interactions. *Res. Immunol.* 146:171-176.
167. Chang, C., A. Rodríguez, M. Carretero, M. López-Botet, J.H. Phillips and L.L. Lanier. 1995. Molecular characterization of human CD94: A type II membrane glycoprotein related to the C-type lectin superfamily. *Eur. J. Immunol.* 25:2433-2437.
168. Lanier, L.L. 1995. The role of natural killer cells in transplantation. *Curr. Opin. Immunol.* 7:626-631.
169. Fernández-Ruiz, E., C. Somoza, F. Sánchez-Madrid and L.L. Lanier. 1995. CD28/CTLA-4 ligands: The gene encoding CD86 (B70/B7.2) maps to the same region as CD80 (B7/B7.1) gene in human chromosome 3q13-q23. *Eur. J. Immunol.* 25:1453-1456.
170. Lanier, L.L. and J.H. Phillips. 1996. Inhibitory MHC class I receptors on NK cells and T cells. *Immunol. Today* 17:86-91.

171. Warren, H.S., B.F. Kinnear, R.L. Kastelein and L.L. Lanier. 1996. Analysis of the costimulatory role of IL-2 and IL-15 in initiating proliferation of resting (CD56^{dim}) human NK cells. *J. Immunol.* 156:3254-3259.
172. Barber, L.D., T.P. Patel, L. Percival, J.E. Gumperz, L.L. Lanier, J.H. Phillips, J.C. Bigge, M.R. Wormald, R.B. Parekh and P. Parham. 1996. Unusual uniformity of the N-linked oligosaccharides HLA-A, -B and -C glycoproteins. *J. Immunol.* 156:3275-3284.
173. D'Andrea, A., C. Chang, K. Bacon, J.H. Phillips and L.L. Lanier. 1995. *Cutting Edge*: Molecular cloning of NKB1: A natural killer cell receptor for HLA-B allotypes. *J. Immunol.* 155:2306-2310.
174. Baker, E., A. D'Andrea, J.H. Phillips, G.R. Sutherland and L.L. Lanier. 1995. Natural killer cell receptor for HLA-B allotypes, NKB1: Map position 19q13.4. *Chromosome Res.* 3:511.
175. Gumperz, J., N. Valiante, P. Parham, L.L. Lanier and D. Tyan. 1996. Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigen types appear genetically regulated, but not linked to major histocompatibility complex haplotype. *J. Exp. Med.* 183:1817-1827.
176. Lanier, L.L. 1995. Unusual lymphocytes: $\gamma\delta$ T cells and NK cells. *The Immunologists* 3:182-184.
177. Barber, L.D., L. Percival, N. Valiante, L. Chen, C. Lee, J.E. Gumperz, J.H. Phillips, L.L. Lanier, J.C. Bigge, R.B. Parekh and P. Parham. 1996. The inter-locus recombinant HLA-B*4601 has high selectivity in peptide binding and functions characteristic of HLA-C. *J. Exp. Med.* 184:735-740.
178. Long, E.O., M. Colonna and L.L. Lanier. 1996. Inhibitory MHC class I receptors on NK and T cells: a standard nomenclature. *Immunol. Today* 17:100.
179. Onishi, M., S. Kinoshita, Y. Morikawa, A. Shibuya, J. Phillips, L.L. Lanier, D.M. Gorman, G.P. Nolan, A. Miyajima and T. Kitamura. 1996. Applications of retrovirus-mediated expression cloning. *Exp. Hematol.* 24:324-329.
180. Strassmann, G., T.A. Springer, S.J. Haskill, C.C. Miraglia, L.L. Lanier and D.O. Adams. 1985. Antigens associated with the activation of murine mononuclear phagocytes in vivo: differential expression of lymphocyte function-associated antigen in the several stages of development. *Cellular Immunol.* 94:265-275.
181. D'Andrea, A. and L.L. Lanier. 1996. NKB1: A killer cell inhibitory receptor (KIR) for class I HLA-B allotypes. In: *Natural killer cell receptors and functions*. Ed. L. Moretta, Karger Publishing House, NY, p. 104.

182. Shibuya, A., D. Campbell, C. Hannum, H. Yssel, K. Franz-Bacon, T. McClanahan, T. Kitamura, J. Nicholl, G.R. Sutherland, L.L. Lanier and J.H. Phillips. 1996. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. *Immunity* 4:573-581.
183. D'Andrea, A., C. Chang, J.H. Phillips and L.L. Lanier. 1996. Regulation of T cell lymphokine production by killer cell inhibitory receptor recognition of self-HLA class I alleles. *J. Exp. Med.* 184:789-794.
184. Fry, A.M., L.L. Lanier and A. Weiss. 1996. Phosphotyrosines in the killer cell inhibitory receptor motif of NKB1 are required for negative signaling and for association with protein tyrosine phosphatase 1C. *J. Exp. Med.* 184:295-300.
185. Phillips, J.H., C. Chang, J. Mattson, J. Gumperz, P. Parham and L.L. Lanier. 1996. CD94 and a novel associated protein (94AP) form a NK cell receptor involved in the recognition of HLA-A, -B and -C allotypes. *Immunity* 5:163-172.
186. Gumperz, J.E., L.D. Barber, N.M. Valiante, L. Percival, J.H. Phillips, L.L. Lanier and P. Parham. 1997. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell inhibitory receptor. *J. Immunol.* 158:5237-5241.
187. Lanier, L.L. 1997. Natural killer cell receptors and MHC class I interactions. *Curr. Opin. Immunol.* 9:126-131.
188. Lanier, L.L. B. Corliss and J.H. Phillips. 1997. Arousal and inhibition of human NK cells. *Immunol. Rev.* 155:145-154.
189. Lanier, L.L. 1997. NK cell receptors for polymorphic MHC class I molecules. In: *Genetic Diversity of HLA: Functional and Medical Implications, Volume II*, Ed. D. Charron, EDK Publishers, Paris, p. 42-45.
190. Houchins, J.P., L.L. Lanier, E. Niemi, J.H. Phillips and J. Ryan. 1997. Natural killer cell cytolytic activity is inhibited by NKG2A and activated by NKG2C. *J. Immunol.* 158:3603-3609.
191. Valiante, N.M., J.H. Phillips, L.L. Lanier and P. Parham. 1996. Killer cell inhibitory receptor recognition of human leukocyte antigen (HLA) class I blocks formation of a pp36/PLC- γ signaling complex in human natural killer (NK) cells. *J. Exp. Med.* 184:2243-2250.
192. Gumperz, J.E., J.C.M. Paterson, V. Litwin, N. Valiante, L.L. Lanier, P. Parham and A.M. Little. 1996. Specificity of two anti-class I HLA monoclonal that block class I recognition by the NKB1 killer cell inhibitory receptor. *Tissue Antigens* 48:278-284.
193. D'Andrea, A., and L.L. Lanier. 1998. Killer cell inhibitory receptor expression by T cells. *Current Topics in Microbiology and Immunology* 230:25-39.

194. Binstadt, B.A., K.M. Brumbaugh, C.J. Dick, A.M. Scharenberg, B.L. Williams, M. Colonna, L.L. Lanier, J. -P. Kinet, R.T. Abraham and P.J. Leibson. 1996. Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. *Immunity* 5:629-638.
195. Lazetic, S., C. Chang, J.P. Houchins, L.L. Lanier and J.H. Phillips. 1996. *Cutting Edge*: Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. *J. Immunol.* 157:4741-4745.
196. Soderstrom, K., B. Corliss, L.L. Lanier and J.H. Phillips. 1997. *Cutting Edge*: CD94/NKG2 is the predominant inhibitory receptor involved in recognition of HLA-G by decidual and peripheral blood NK cells. *J. Immunol.* 159:1072-1075.
197. Jaleco, A.C., B. Blom, P. Res, K. Weijer, L.L. Lanier, J.H. Phillips and H. Spits. 1997. Fetal liver contains committed NK progenitors, but is not a site for development of CD34+ cells into T cells. *J. Immunol.* 159:694-702.
198. Lanier, L.L. 1997. NK cells: from no receptors to too many. *Immunity* 6:371.
199. Renedo, M., A. Rodriguez, I. Arce, M. Carretero, L.L. Lanier, M. Lopez-Botet and E. Fernandez-Ruiz. 1997. The human natural killer cell genetic complex is located on chromosome 12p12-p13. *Immunogenetics* 43:307.
200. Lanier, L.L. 1998. NK cell receptors. *Annu. Rev. Immunol.* 16:359-393.
201. Meyaard, L., G.J. Adema, C. Chang, E. Woollatt, G.R. Sutherland, L.L. Lanier and J.H. Phillips. 1997. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. *Immunity* 7:283-290.
202. Bakker, A.B.H., J.H. Phillips, C.G. Figdor and L.L. Lanier. 1998. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, $\gamma\delta$ T cells, and antigen-specific CTL. *J. Immunol.* 160:5239-5245.
203. Valiante, N.M., M. Uhrberg, H.G. Shilling, K. Lienert-Weidenbach, K.L. Arnett, A. D'Andrea, J.H. Phillips, L.L. Lanier and P. Parham. 1997. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. *Immunity* 7:739-751.
204. Uhrberg, M., N.M. Valiante, B.P. Shum, H.G. Shilling, K. Lienert-Weidenbach, B. Corliss, D. Tyan, L.L. Lanier and P. Parham. 1997. Human diversity in killer cell inhibitory receptor genes. *Immunity* 7:753-763.
205. Lanier, L.L., B.C. Corliss, J. Wu, C. Leong and J.H. Phillips. 1998. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. *Nature* 391:703-707.

206. Chang, C. and L.L. Lanier. 2000. Use of cDNA library expression cloning to identify components of heterodimeric receptor complexes. In: Natural Killer Cells: Functions, receptors, and clinical applications. Methods in Molecular Biology. K.S. Campbell and M. Colonna, Ed. Humana Press, p. 273-281.
207. Braud, V.M., D.S.J. Allan, C.A. O'Callaghan, K. Soderstrom, A. D'Andrea, G.S. Ogg, S. Lazetic, N.T. Young, J.I. Bell, J.H. Phillips, L.L. Lanier and A.J. McMichael. 1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B, and C. *Nature* 391:795-799.
208. Leong, C.C., T. Chapman, P. Bjorkman, D. Formankova, E. Mocarski, J.H. Phillips and L.L. Lanier. 1998. Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility and a viral class I homolog. *J. Exp. Med.* 187:1681-1687.
209. Lanier, L.L. 1998. Follow the Leader: NK cell receptors for classical and nonclassical MHC class I. *Cell* 92:705-707.
210. Tangye, S.G., J.H. Phillips, L.L. Lanier, J.E. deVries and G. Aversa. 1998. CD148: a receptor-type protein tyrosine phosphatase involved in the regulation of human T cell activation. *J. Immunol.* 161:3249-3255.
211. Lanier, L.L. 1998. Activating and inhibitory NK cell receptors. In: Mechanisms of Lymphocyte Activation and Immune Regulation VII: Molecular determinants of microbial immunity. Ed. S. Gupta, A. Sher, and R. Ahmed. Plenum Press, NY. p. 13-18.
212. Barton, K., N. Muthusamy, C. Fischer, C.N. Ting, T.L. Walunas, L.L. Lanier, J.M. Leiden. 1998. The Ets-1 transcription factor is required for the development of the natural killer cells in mice. *Immunity* 9:555-563.
213. Smith, K.M., J. Wu, A.B.H. Bakker, J.H. Phillips, and L.L. Lanier. 1998. *Cutting Edge*: Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors. *J. Immunol.* 161:7-10.
214. Lanier, L.L., B.C. Corliss, J. Wu, and J.H. Phillips. 1998. Association of DAP12 with activating CD94/NKG2C NK cell receptors. *Immunity* 8:693-701.
215. Tangye, S.G., J. Wu, G. Aversa, J.E. deVries, L.L. Lanier, and J.H. Phillips. 1998. *Cutting Edge*: Negative regulation of human T cell activation by the receptor-type protein tyrosine phosphatase CD148. *J. Immunol.* 161:3803-3807.
216. Shibuya, A., L.L. Lanier, and J.H. Phillips. 1998. Protein kinase C is involved in the regulation of both signaling and adhesion mediated by DNAX accessory molecule-1 receptor. *J. Immunol.* 161:1671-1676.
217. Meyaard, L., J. Hurenkamp, H. Clevers, L.L. Lanier, and J.H. Phillips. 1999. Leukocyte-associated Ig-like receptor-1 functions as an inhibitory receptor on cytotoxic T cells. *J. Immunol.* 162:5800-5804.

218. Allan, D.S., M. Colonna, L.L. Lanier, T.D. Churakova, J.S. Abrams, S.A. Ellis, A.J. McMichael, and V.M. Braud. 1999. Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells. *J. Exp. Med.* 189:1149-1155.
219. Trinchieri, G. and L.L. Lanier. 2001. Functions of Natural Killer Cells. In: Williams' Hematology 6th Ed., E. Beutler et al. ed., McGraw Hill, p. 959-963.
220. Shibuya, K., L.L. Lanier, J.H. Phillips, H.D. Ochs, K. Shimizu, E. Nakayama, H. Nakauchi, and A. Shibuya. 1999. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. *Immunity* 11:615-623.
221. Tangye, S.G., S. Lazetic, E. Woollatt, G.R. Sutherland, L.L. Lanier, and J.H. Phillips. 1999. *Cutting Edge*: Human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. *J. Immunol.* 162:6981-6985.
222. Lanier, L.L. 2000. Natural killer cells. In: Samter's Immunologic Diseases, 6th Ed., K.F. Austen, ed., Lippincott, Williams and Wilkins, Chapter 19, p. 206-209.
223. Lanier, L.L. 2000. The origin and functions of natural killer cells. *Clin. Immunol.* 95:S14-S18.
224. Bakker, A.B.H., E. Baker, G.R. Sutherland, J.H. Phillips, and L.L. Lanier. 1999. Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. *Proc. Natl. Acad. Sci. USA* 96:9792-9796.
225. Castro, A.G., T.M. Hauser, B.G. Cocks, J. Abrams, S. Zurawski, T. Churakova, F. Zonin, D. Robinson, S. Tangye, G. Aversa, K.E. Nicols, J. de Vries, L.L. Lanier, and A. O'Garra. 1999. Molecular and functional characterization of mouse signaling lymphocytic activation molecule (SLAM): Differential expression and responsiveness in Th1 and Th2 cells. *J. Immunol.* 163:5860-5870.
226. Lanier, L.L. 1999. Natural killer cells fertile with receptors for HLA-G? *Proc. Natl. Acad. Sci. USA* 96:5343-5345.
227. Bauer, S., V. Groh, J. Wu, A. Steinle, J.H. Phillips, L.L. Lanier, and T. Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. *Science* 285:727-729.
228. Wu, J., Y. Song, A.B.H. Bakker, S. Bauer, T. Spies, L.L. Lanier, and J.H. Phillips. 1999. An activating immunoreceptor complex formed by NKG2D and DAP10. *Science* 285:730-732.
229. Lanier, L.L. Human NK cell receptors. 2000. *Semin. Immunol.* 12:99-100.

230. Bakker, A.B.H., J. Wu, J.H. Phillips, and Lanier, L.L. 2000. NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. *Hum. Immunol.* 61:18-27.
231. Lanier, L.L. 2000. Turning on NK cells. *J. Exp. Med.* 191:1259-1262.
232. Pauza, M., K.M. Smith, H. Neal, C. Reilly, L.L. Lanier, and D. Lo. 2000. Transgenic expression of Ly-49A in thymocytes alters repertoire selection. *J. Immunol.* 164:884-892.
233. Tangye, S., J.H. Phillips, and L.L. Lanier. 2000. The CD2-subset of the Ig superfamily of cell surface molecules: receptor-ligand pairs expressed by NK cells and other immune cells. *Semin. Immunol.* 12:149-157.
234. Lanier, L.L. 2002. CD94 and NKG2. *Encyclopedia of Molecular Medicine*, ed. T.E. Creighton, J. Wiley & Sons, p. 686-688.
235. Muench, M.O., L. Humeau, B. Paek, T. Ohkubo, L.L. Lanier, C.T. Albanese, and A. Barcena. 2000. Differential effects of interleukin-3, interleukin-7, interleukin-15, and granulocyte-macrophage colony-stimulating factor in the generation of natural killer and B cells from primitive human fetal liver progenitors. *Exp. Hematol.* 28:961-973.
236. Paloneva, J., M. Kestila, J. Wu, A. Salminen, T. Bohling, V. Ruotsalainen, P. Hakola, A.B.H. Bakker, J.H. Phillips, P. Pekkarinen, L.L. Lanier, T. Timonen, and L. Peltonen. 2000. Loss-of-function mutations in *TYROBP (DAP12)* result in a presenile dementia with bone cysts. *Nature Genetics* 25:357-361.
237. Cerwenka, A., A.B.H. Bakker, T. McClanahan, J. Wagner, J. Wu, J.H. Phillips, and L.L. Lanier. 2000. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. *Immunity* 12:721-727.
238. Khakoo, S.I., R. Rajalingam, B.P. Shum, K. Weidenbach, L. Flodin, D.G. Muir, F. Cananvez, S.L. Cooper, N.M. Valiante, L.L. Lanier, and P. Parham. 2000. Rapid evolution of NK cell receptor systems demonstrated by comparison of chimpanzees and humans. *Immunity* 12:687-698.
239. Ravetch, J.V. and L.L. Lanier. 2000. Immune inhibitory receptors. *Science* 290:84-89.
240. Yim, D., H-B. Jie, L.L. Lanier, and Y.B. Kim. 2000. Molecular cloning, gene structure, and expression pattern of pig immunoreceptor DAP12. *Immunogenetics* 51:436-442.
241. Lanier, L.L., M. Peterson, and E.O. Long. 2001. Antibody reactivity with NK receptors expressed on transfected cells. In: *Leucocyte Typing VII*, D. Mason et al., Eds. Oxford University Press, p. 9-10.
242. Bakker, A.B.H., R.M. Hoek, A. Cerwenka, B. Blom, L. Lucian, T. McNeil, R. Murray, J.H. Phillips, J.D. Sedgwick, and L.L. Lanier. 2000. DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming. *Immunity* 13:345-353.

243. Tangye, S.G., J.H. Phillips, L.L. Lanier, and K.E. Nichols. 2000. *Cutting Edge*: Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. *J. Immunol.* 165:2932-2936.
244. Lanier, L.L. and A.B.H. Bakker. 2000. The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. *Immunology Today* 21:611-614.
245. Tangye, S.G., H. Cherwinski, L.L. Lanier, and J.H. Phillips. 2000. 2B4-mediated activation of human natural killer cells. *Mol. Immunol.* 37:493-501.
246. Wu, J., H. Cherwinski, T. Spies, J.H. Phillips, and L.L. Lanier. 2000. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. *J. Exp. Med.* 192:1059-1067.
247. Shibuya, A, N. Sakamoto, Y. Shimizu, K. Shibuya, M. Osawa, T. Hiroyama, H.J. Eyre, G.R. Sutherland, Y. Endo, T. Fujita, T. Miyabayashi, S. Sakano, T. Tsuji, E. Nakayama, J.H. Phillips, L.L. Lanier, and H. Nakauchi. 2000. Fc α/μ receptor mediates endocytosis of IgM-coated microbes. *Nature Immunology* 1:441-446.
248. Lanier, L.L. 2001. On guard – activating NK cell receptors. *Nature Immunology* 2:23-27.
249. Lanier, L.L. 2001. Face off – the interplay between activating and inhibitory immune receptors. *Curr. Opin. Immunol.* 13:326-331.
250. Cerwenka, A., and L.L. Lanier. 2001. Ligands for natural killer cell receptors: redundancy or specificity. *Immunol. Rev.* 181:158-169.
251. Uhrberg, M., N.M. Valiante, N.T. Young, L.L. Lanier, J.H. Phillips, and P. Parham. 2001. The repertoire of killer cell Ig-like receptor and CD94:NKG2A receptors in T cells: clones sharing identical $\alpha\beta$ TCR rearrangements express highly diverse killer cell Ig-like receptor patterns. *J. Immunol.* 166:3923-3932.
252. Young, N.T., M. Uhrberg, J.H. Phillips, L.L. Lanier, and P. Parham. 2001. Differential expression of leukocyte receptor complex-encoded Ig-like receptors correlates with the transition from effector to memory CTL. *J. Immunol.* 166:3933-3941.
253. Daws, M.R., L.L. Lanier, W.E. Seaman, and J.C. Ryan. 2001. Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family. *Eur. J. Immunol.* 31:783-791.
254. Kadowaki, N., S. Antonenko, S. Ho, M-C. Rissoan, V. Soumelis, S.A. Porcelli, L.L. Lanier, and Y-J. Liu. 2001. Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. *J. Exp. Med.* 193:1221-1226.
255. Steinle, A., L. Pingwei, D.L. Morris, V. Groh, L.L. Lanier, R.K. Strong, and Spies, T. 2001. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. *Immunogenetics* 53:279-287.

256. Yim, D., H-B Jie, J. Sotiriadis, Y-S. Kim, K-S. Kim, M.F. Rothschild, L.L. Lanier and Y.B. Kim. 2001. Molecular cloning and characterization of pig immunoreceptor DAP10 and NKG2D. *Immunogenetics* 53:243-249.
257. Andre, P., R. Biassoni, M. Colonna, D. Cosman, L.L. Lanier, E.O. Long, M. Lopez-Botet, A. Moretta, L. Moretta, P. Parham, J. Trowsdale, E. Vivier, N. Wagtmann, and M.J. Wilson, 2001. New nomenclature for MHC receptors. *Nature Immunology* 2:661.
258. Warren, H.S., A.J. Campbell, J.C. Waldron, and L.L. Lanier. 2001. Biphasic response of NK cells expressing both activating and inhibitory killer Ig-like receptors. *Int. Immunol.* 13:1043-1052.
259. Cooper, M.D., L.L. Lanier, M.E. Conley, and J.M. Puck. 2003. Immunodeficiency disorders. *Hematology* 2003 p. 314-319.
260. O'Callaghan, C.A., A. Cerwenka, B.E. Willcox, L.L. Lanier, and P.J. Bjorkman. 2001. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60. *Immunity* 15:201-211.
261. Arase, H., T. Saito, J.H. Phillips, and L.L. Lanier. 2001. *Cutting Edge*: The mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b ($\alpha 2$ integrin, very late antigen-2). *J. Immunol.* 167:1141-1144.
262. Cerwenka, A., and L.L. Lanier. 2001. Natural killer cells, viruses and cancer. *Nature Reviews Immunology* 1:41-49.
263. Cerwenka, A., J.L. Baron, and L.L. Lanier. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor *in vivo*. *Proc. Natl. Acad. Sci. USA* 98:11521-11526.
264. Lanier, L.L. 2001. A renaissance for the tumor immunosurveillance hypothesis. *Nature Medicine* 7:1178-1180.
265. Lanier, L.L. and A. Aderem. 2002. Innate Immunity. *Curr. Opin. Immunol.* 14:85-86.
266. Masuda, H., Y. Saeki, M. Nomura, K. Shida, M. Matsumoto, M. Ui, L.L. Lanier, and T. Seya. 2002. High levels of RAE-1 isoforms on mouse tumor cell lines assessed by anti-'pan' RAE-1 antibody confer tumor susceptibility to NK cells. *Biochem. Biophys. Res. Commun.* 290:140-145.
267. Cerwenka, A., C.A. O'Callaghan, J.A. Hamerman, R. Yadav, W. Ajayi, D.C. Roopenian, S. Joyce, and L.L. Lanier. 2002. *Cutting Edge*: The minor histocompatibility antigen H60 peptide interacts with both H-2K^b and NKG2D. *J. Immunol.* 168:3131-3134.

268. Naper, C., S. Hayashi, L. Kveberg, E.C. Niemi, L.L. Lanier, J.T. Vaage, and J.C. Ryan. 2002. Ly-49s3 is a promiscuous activating rat NK cell receptor for nonclassical MHC class I-encoded target ligands. *J. Immunol.* 169:22-30.
269. Arase, H., and L.L. Lanier. 2002. Viral-driven evolution of natural killer cell receptors. *Microbes Infect.* 4:1505-1512.
270. Arase, H., E.S. Mocarski, A.E. Campbell, A.B. Hill, and L.L. Lanier. 2002. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. *Science* 296:1323-1326.
271. Ogasawara, K., S.K. Yoshinaga, and L.L. Lanier. 2002. Inducible costimulator costimulates cytotoxic activity and IFN- γ production in activated murine NK cells. *J. Immunol.* 169:3676-3685.
272. Lodoen, M., K. Ogasawara, J.A. Hamerman, H. Arase, J.P. Houchins, E.S. Mocarski, and L.L. Lanier. 2003. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. *J. Exp. Med.* 197:1245-1253.
273. Michaelsson, J., C. Teixeira de Matos, A. Achour, L.L. Lanier, K. Karre, and K. Soderstrom. 2002. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. *J. Exp. Med.* 196:1403-1414.
274. Ogasawara, K., J.A. Hamerman, H. Hsin, S. Chikuma, H. Bour-Jordon, T. Chen, T. Pertel, C. Carnaud, J.A. Bluestone and L.L. Lanier. 2003. Impairment of NK cell function by NKG2D modulation in NOD mice. *Immunity* 18:41-51.
275. Lanier, L.L. 2003. Natural killer cell receptor signaling. *Curr. Opin. Immunol.* 15:308-314.
276. Cerwenka, A., and L.L. Lanier. 2003. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. *Tissue Antigens* 61:335-343.
277. Westgaard, I.H., E. Dissen, K.M. Torgensen, S. Lazetic, L.L. Lanier, J.H. Phillips, and S. Fossum. 2003. The lectin-like receptor KLRE1 inhibits natural killer cell cytotoxicity. *J. Exp. Med.* 197:1551-1561.
278. Wu, J., and L.L. Lanier. 2003. NK cells and cancer. *Adv. Cancer Research* 90:127-156.
279. Humphrey, M.B., K. Ogasawara, W. Yao, S.C. Spusta, M.R. Daws, N.E. Lane, L.L. Lanier, and M.C. Nakamura. 2004. The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. *J. Bone Miner. Res.* 19:224-234.
280. Zompi, S., J.A. Hamerman, K. Ogasawara, E. Schweighoffer, V.L.J. Tybulewicz, J.P. DiSanto, L.L. Lanier, and F. Colucci. 2003. NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. *Nature Immunology* 4:565-572.

281. Arase, H. and L.L. Lanier. 2004. Specific recognition of virus-infected cells by paired NK receptors. *Rev. Med. Virol.* 14:83-93.
282. Hamerman, J.A., K. Ogasawara, and L.L. Lanier. 2004. *Cutting Edge*: Toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor. *J. Immunol.* 172:2001-2005.
283. Shiratori, I., K. Ogasawara, T. Saito, L.L. Lanier, and H. Arase. 2004. Activation of natural killer cells and dendritic cells upon recognition of a novel CD99-like ligand by paired immunoglobulin-like type 2 receptor. *J. Exp. Med.* 199:525-533.
284. Berahovich, R.D., N.L. Lai, Z. Wei, L.L. Lanier, and T.J. Schall. 2006. Evidence for NK cell subsets based on chemokine receptor expression. *J. Immunol.* 177:7833-7840.
285. Rosen, D.B., M. Araki, J.A. Hamerman, T. Chen, T. Yamamura, and L.L. Lanier. 2004. A structural basis for the association of DAP12 with mouse, but not human, NKG2D. *J. Immunol.* 173:2470-2478.
286. Tahara-Hanaoka, S., K. Shibuya, Y. Onoda, H. Zhang, S. Yamazaki, A. Miyamoto, S.-I. Honda, L.L. Lanier, and A. Shibuya. 2004. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). *Int. Immunol.* 16:533-538.
287. Lanier, L.L. 2005. NKG2D in innate and adaptive immunity. *Adv. Exp. Med. Biol.* 560:51-56.
288. Trinchieri, G. and L.L. Lanier. 2005. Functions of Natural Killer cells. In: Williams' Hematology 7th Ed., E. Beutler et al. ed., McGraw Hill, Chapter 79, p. 1077-1082.
289. Mócsai, A., M.B. Humphrey, J.A.G. Van Ziffle, Y. Hu, A. Burghardt, S.C. Spusta, S. Majumdar, L.L. Lanier, C.A. Lowell, and M.C. Nakamura. 2004. The immunomodulatory adapter proteins DAP12 and Fc receptor γ -chain (FcR γ) regulate development of functional osteoclasts through the Syk tyrosine kinase. *Proc. Natl. Acad. Sci. USA*, 101:6158-6163.
290. Ogasawara, K., J.A. Hamerman, L.R. Ehrlich, H. Bour-Jordon, P. Santamaria, J.A. Bluestone, and L.L. Lanier. 2004. NKG2D blockade prevents autoimmune diabetes in NOD mice. *Immunity* 20:757-767.
291. Lanier, L.L. 2004. NKG2D. *J. Biol. Regul. Homeost. Agents* 17:338-340.
292. Zingoni, A., T. Sornasse, B.G. Cocks, Y. Tanaka, A. Santoni, and L.L. Lanier. 2005. NK cell regulation of T cell-mediated responses. *Mol. Immunol.* 42:451-454.
293. Takaki, R., and L.L. Lanier. 2005. Immune surveillance in cancer. In: *Viral and Immunological Malignancies*, P.A. Volberding and J. Palefsky, eds. BC Decker Inc. Publisher, Hamilton, Ontario, Canada, Chapter 3, p. 26-39.

294. Zingoni, A., T. Sornasse, B.G. Cocks, Y. Tanaka, A. Santoni, and L.L. Lanier. 2004. Cross-talk between activated human NK cells and CD4⁺ T cells via OX40-OX40 ligand interactions. *J. Immunol.* 173:3716-3724.
295. Lodoen, M.B. and L.L. Lanier. 2005. Viral modulation of NK cell immunity. *Nature Reviews Microbiology* 3:59-69.
296. Meresse, B., Z. Chen, C. Ciszewski, M. Tretiakova, G. Bhagut, T.N. Krausz, D.H. Raulet, L.L. Lanier, V. Groh, T. Spies, E.C. Ebert, P.H. Green, and B. Jabri. 2004. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. *Immunity* 21:357-366.
297. Voehringer, D., D.B. Rosen, L.L. Lanier, and R.M. Locksley. 2004. CD200 receptor family members represent novel DAP12-associated activating receptors on basophils and mast cells. *J. Biol. Chem.* 279:54117-54123.
298. Hamerman, J.A., K. Ogasawara, and L.L. Lanier. 2005. NK cells in innate immunity. *Curr. Opin. Immunol.* 17:29-35.
299. Lodoen, M.B., G. Abenes, S. Umamoto, J.P. Houchins, F. Liu, and L.L. Lanier. 2004. The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions. *J. Exp. Med.* 200:1075-1081.
300. Lanier, L.L. 2005. NK cell recognition. *Annu. Review Immunol.* 23:225-274.
301. Richie Ehrlich, L.I., K. Ogasawara, J.A. Hamerman, R. Takaki, A. Zingoni, J.P. Allison, and L.L. Lanier. 2005. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8⁺ T cells. *J. Immunol.* 174:1922-1931.
302. Bach, J-F., A. Bendelac, M.B. Brenner, H. Cantor, G. De Libero, M. Kronenberg, L.L. Lanier, D.H. Raulet, M.J. Shlomchik, and M.G. von Herrath. 2004. The role of innate immunity in autoimmunity. *J. Exp. Med.* 200:1527-1531.
303. Lanier, L.L. 2005. First sighting of the elusive T cell antigen receptor. *J. Immunol.* 174:1143.
304. Hamerman, J.A., N. K. Tchao, C.A. Lowell, and L.L. Lanier. 2005. Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. *Nature Immunology* 6:579-586.
305. Lanier, L.L. 2005. Missing self, NK cells and the White Album. *J. Immunol.* 174:6565.
306. Desrosiers, M-P., A. Kielczewska, J-C. Loredó-Osti, S.G. Adam, A.P. Makrigiannis, S. Lemieux, T. Pham, M.B. Lodoen, K. Morgan, L.L. Lanier, and S.M. Vidal. 2005. Epistasis between Klra and major histocompatibility complex class I loci is associated with a new

mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection. *Nature Genetics* 37:593-599.

307. Vidal, S.M., and L.L. Lanier. 2005. NK cell recognition of mouse cytomegalovirus-infected cells. *Current Topics in Microbiology and Immunology* 298:183-206.
308. Takaki, R., Y. Hayakawa, A. Nelson, P.V. Sivakumar, S. Hughes, M.J. Smyth, and L.L. Lanier. 2005. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. *J. Immunol.* 175:2167-2173.
309. Humphrey, M.B., L.L. Lanier, and M.C. Nakamura. 2005. Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. *Immunol. Rev.* 208:50-65.
310. Shiratori, I., M. Tamaguchi, M. Suzukawa, K. Yamamoto, L.L. Lanier, T. Saito, and H. Arase. 2005. Down-regulation of basophil function by human CD200 and human herpesvirus-8 CD200. *J. Immunol.* 175:4441-4449.
311. Ogasawara, K., J. Benjamin, R. Takaki, J.H. Phillips, and L.L. Lanier. 2005. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. *Nature Immunology* 6:938-945.
312. Hamerman, J.A. and L.L. Lanier. 2006. Inhibition of immune responses by ITAM-bearing receptors. *Science STKE* volume 2006, issue 320, pp. re1.
313. Rosen, D.B., J. Bettadapura, M. Alsharifi, P.A. Mathew, H.S. Warren, and L.L. Lanier. 2005. *Cutting Edge*: Lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. *J. Immunol.* 175:7796-7799.
314. Ogasawara, K. and L.L. Lanier. 2005. NKG2D in NK and T cell-mediated immunity. *J. Clin. Immunol.* 25:534-540.
315. Humphrey, M.B., M.R. Daws, S.C. Spusta, E.C. Niemi, J.A. Torchia, L.L. Lanier, W.E. Seaman, and M.C. Nakamura. 2006. TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. *J. Bone Mineral Research* 21:237-245.
316. Routes, J.M., S. Ryan, K. Morris, R. Takaki, A. Cerwenka, and L.L. Lanier. 2005. Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. *J. Exp. Med.* 202:1477-1482.
317. Chen, S., H. Kawashima, J.B. Lowe, L.L. Lanier, and M. Fukuda. 2005. Suppression of tumor formation in lymph nodes by L-selectin-mediated natural killer cell recruitment. *J. Exp. Med.* 202:1679-1689.
318. Bui, J.D., L.N. Carayannopoulos, L.L. Lanier, W.M. Yokoyama, and R.D. Schreiber. 2006. Interferon-dependent downregulation of the NKG2D-ligand H60 on tumors. *J. Immunol.* 176:905-913.

319. Chan, C., E. Crafton, H-N., Fan, K. Yoshimura, J. Flook, D. Brockstedt, T.W. Dubensky, M.F. Stins, L.L. Lanier, D.M. Pardoll, and F. Housseau. 2006. Innate killer-dendritic cells directly link innate and adaptive immunity. *Nature Medicine* 12:207-213.
320. Hesslein, D.G.T., R. Takaki, M.L. Hermiston, A. Weiss, and L.L. Lanier. 2006. Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production. *Proc. Natl. Acad. Sci. USA* 103:7012-7017.
321. Lodoen, M. and L.L. Lanier. 2006. NK cells as an initial defense against pathogens. *Curr. Opin. Immunol.* 18:391-398.
322. Shiow, L.R., D.B. Rosen, N. Brdickova, Y. Xu, J. An, L.L. Lanier, J.G. Cyster, and M. Matloubian. 2006. CD69 acts downstream of interferon- α/β to inhibit S1P₁ and lymphocyte egress from lymphoid organs. *Nature* 440:540-544.
323. Cao, W., D.B. Rosen, T. Ito, L. Bover, M. Bao, G. Watanabe, L. Zhang, L.L. Lanier, and Y-J. Liu. 2006. Plasmacytoid dendritic cell-specific receptor ILT7/Fc ϵ RI γ inhibits Toll-like receptor-induced interferon production. *J. Exp. Med.* 203:1399-1405.
324. Lanier, L.L. 2006. Viral immunoreceptor tyrosine-based activation motif (ITAM)-mediated signaling in cell transformation and cancer. *Trends in Cell Biology* 16:388-390.
325. Meresse, B., S.A. Curran, C. Ciszewski, G. Orbelyan, M. Setty, G. Bhagat, L. Lee, M. Tretiakova, C. Semrad, E. Kistner, R.J. Winchester, V. Braud, L.L. Lanier, D.E. Geraghty, P.H. Green, S. Guandalini, and B. Jabri. 2006. Reprogramming of CTLs into natural killer-like cells in celiac disease. *J. Exp. Med.* 203:1343-1355.
326. Hamerman, J.A., J.R. Jarjoura, M.B. Humphrey, M.C. Nakamura, W.E. Seaman, and L.L. Lanier. 2006. *Cutting Edge*: Inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM-2) and DAP12. *J. Immunol.* 174:2051-2055.
327. Takaki, R., S.R. Watson, and L.L. Lanier. 2006. DAP12, an adapter protein with dual functionality. *Immunological Reviews*, 214:118-129.
328. Kielczewska, A., H-S. Kim, L.L. Lanier, N. Dimasi, and S.M. Vidal. 2007. Critical residues at the Ly49 Natural Killer receptor's homodimer interface determine functional recognition of m157, a mouse cytomegalovirus MHC class I-like protein. *J. Immunol.* 178:369-377.
329. Lanier, L.L. 2006. NK cells – roundup. *Immunological Reviews* 214:5-8.
330. Mocsai, A., C.L. Abram, Z. Jakus, Y. Hu, L.L. Lanier, and C.A. Lowell. 2006. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. *Nature Immunology* 7:1326-1333.

331. Carr, W.H., D.B. Rosen, H. Arase, D.F. Nixon, J. Michaelsson, and L.L. Lanier. 2007. *Cutting Edge*: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. *J. Immunol.* 178:647-651.
332. Spits, H., and L.L. Lanier. 2007. Natural killer or dendritic: What's in a name? *Immunity* 26:11-15.
333. Adams, E.J., Z.S. Juo, R.T. Venook, M.J. Boulanger, H. Arase, L.L. Lanier, and K.C. Garcia. 2007. Structural elucidation of m157, a mouse cytomegalovirus, MHC-like ligand for natural killer cell Ly49 receptors. *Proc. Natl. Acad. Sci. USA* 104:10128-10133.
334. Lanier, L.L. 2007. Back to the future – defining NK cells and T cells. *Eur. J. Immunol.* 37:1424-1426.
335. Ballan, W.M., B-A. N. Vu, B.R. Long, C.P. Loo, J. Michaelsson, J.D. Barbour, L.L. Lanier, A.A. Wiznia, J. Abadi, G.J. Fennelly, M.G. Rosenberg, and D.F. Nixon. 2007. Natural killer cell changes in perinatally HIV-1 infected children. *J. Immunol.* 179:3362-3370.
336. Wu, Y., J. Torchia, W. Yao, N.E. Lane, L.L. Lanier, M.C. Nakamura, and M.B. Humphrey. 2007. Bone microenvironment specific roles of ITAM signaling in bone remodeling induced by acute estrogen-deficiency. *PLoS ONE*. Jul 4;2:e586.
337. Cao, W., L. Zhang, D.B. Rosen, L. Bover, G. Watanabe, M. Bao, L.L. Lanier, and Y-J. Liu. 2007. BDCA2 and FcεRIγ complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells. *Plos Biology*, Sep 11;5(10):e248.
338. Lanier, L.L. 2007. Presidential Address – NK cells, null no more! *J. Immunol.* 179:3385-3388.
339. Michaelsson, J., B.R. Long, C.P. Loo, L.L. Lanier, G. Spotts, F.M. Hecht, and D.F. Nixon. 2007. Immune reconstitution of CD56^{dim} NK cells in primary HIV-1-infected individuals treated with interleukin-2. *J. Infectious Diseases*, In press.
340. Lanier, L.L. 2007. KLRK1 (killer cell lectin-like receptor subfamily K, member 1). *Atlas Genet Cytogenet Oncol Haematol*. July 2007
<http://AtlasGeneticsOncology.org/Genes/KLRK1ID41094ch12p13.html>
341. Kim, J., C.K. Chang, T. Hayden, F-C. Liu, J. Benjamin, J.A. Hamerman, L.L. Lanier, and S-M. Kang. 2007. The activating immunoreceptor NKG2D and its ligands are involved in allograft transplantation rejection. *J. Immunol.*, In press.
342. Chu, C-L., Y-L. Yu, K-Y. Shen, C.A. Lowell, L.L. Lanier, and J.A. Hamerman. 2007. Increased TLR responses in dendritic cells lacking the ITAM-containing adapters DAP12 and FcRγ. *Eur. J. Immunol.*

343. Vilarinho, S., K. Ogasawara, S. Nishimura, L.L. Lanier, and J.L. Baron. 2007. Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. *Proc. Natl. Acad. Sci. U.S.A.*, In press.

Patents:

Lanier, L.L. and J.H. Phillips. Method for monitoring activated cell subpopulations. U.S. Patent #4,599,304, issued July 8, 1986.

Lanier, L.L. and N.L. Warner. Differentiation of natural killer cell subpopulations of cells. U.S. Patent #4,607,007, issued August 19, 1986.

Lanier, L.L. J.H. Phillips, and A.L. Jackson. Identification of NK cells and cytotoxic T lymphocytes. U.S. Patent #4,895,796, issued January 23, 1990.

Phillips, J.H., A. Nagler, and L.L. Lanier. Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells. U.S. Patent #5,041,289, issued August 20, 1991.

Lanier, L.L., and J.H. Phillips. CD3 zeta co-associated complex on CD16- NK cells. U.S. Patent #5,124,251, issued June 23, 1992.

Litwin, V.M., J.E. Gumperz, P.R. Parham, J.H. Phillips Jr., and L.L. Lanier. Antibodies to mammalian NK antigens and uses. U.S. Patent #5,770,387, issued June 23, 1998.

Chang, C., J. Aramburu Beltran, M. Lopez-Botet, J.H. Phillips Jr., and L.L. Lanier. Nucleic acids encoding Kp43 protein and antigenic fragments thereof. U.S. Patent #5,811,284, issued September 22, 1998.

Chang, C., L.L. Lanier, and J.H. Phillips Jr. Purified mammalian NK antigens and related reagents. U.S. Patent #5,965,401, issued October 12, 1999.

Adema, G.J., L. Meyaard, D.M. Gorman, T. McClanahan, L.L. Lanier, J.H. Phillips Jr. Ig superfamily 'dla' receptors expressed in monocytes. U.S. Patent #6,140,076, issued October 31, 2000.

Bakker, A.G.H., J.H. Phillips, and L.L. Lanier. Nucleic acids encoding mammalian cell membrane protein MDL-1. U.S. Patent # 6,416,973, issued July 9, 2002.

Adema, G.J., L. Meyaard, D.M. Gorman, T.K. McClanahan, S.M. Zurawski, G. Zurawski, L.L. Lanier, and J.H. Phillips. Antibodies that specifically bind DNAX leukocyte associated immunoglobulin-like receptor. U.S. Patent # 6,479,638 B1, issued November 12, 2002.

Bakker, A.B.H., J.H. Phillips, and L.L. Lanier. Antibodies and fragments thereof to MDL-1 protein. U.S. Patent # 6,953,843 B2, issued October 11, 2005.

Adema, G.J., L. Meyaard, D.M. Gorman, T.K. McClanahan, S.M. Zurawski, G. Zurawski, L.L. Lanier, and J.H. Phillips. Mammalian cell membrane proteins: related reagents. U.S. Patent pending.

Barclay, A.N., M. Brown, D.M. Gorman, L.L. Lanier, G.J. Wright, H. Cherwinski, J.H. Phillips, R.M. Hoek, and J.D. Sedgwick. OX2 receptor homologs. U.S. Patent pending.

Adema, G.J., L. Meyaard, D.M. Gorman, T.K. McClanahan, S.M. Zurawski, G. Zurawski, L.L. Lanier, and J.H. Phillips. Antibodies that specifically bind to FDF03. U.S. Patent pending.

Bakker, A.B.H., J.H. Phillips, and L.L. Lanier. Mammalian cell membrane proteins; related reagents. U.S. Patent pending.

Lanier, L.L., K. Ogasawara, and J.A. Bluestone. Modulation of NKG2D, U.S. Patent pending.

Research Support - Current

ACTIVE

Grant Number: R37 AI066897 PI: Lewis L. Lanier
Dates of Project: 03/01/06-02/28/11 Granting Agency: NIH NIAID
Title: NK and T Cell Costimulation by NKG2D/DAP10
Amount: \$250,000 Annual Direct Costs

The objective of this grant is to study the structural and signaling properties of the NKG2D - DAP10 receptor complex on T cells and NK cells and to study the biological function of this receptor in gene-deficient mice. Lewis Lanier is PI of the grant and responsible for all aspects of the program.

Grant Number: R01AI068129 PI: Lewis L. Lanier
Dates of Project: 02/15/06-01/31/11 Granting Agency: NIH NIAID
Title: NK Cell Receptors and Their Ligands
Amount: \$250,000 Annual Direct Costs

The objective of this grant is to study the structure and biological role of receptors on NK cells that associate with the ITAM-bearing adapter molecules DAP12, FcεRIγ, and ζ. Lewis Lanier is PI of the grant and responsible for all aspects of the program.

Grant Number: R01 CA095137 PI: Lewis L. Lanier
Dates of Project: 02/14/03-01/31/08 Granting Agency: NIH NCI
Title: RAE-1 family of proteins in innate and adaptive immunity
Amount: \$200,250 Annual Direct Costs

The objective of this grant is to study the role of the RAE-1 family of proteins in anti-microbial immunity, mediated by NK cells, CTL and activated macrophages. Lewis Lanier is the PI of the grant and responsible for all aspects of the program.

Grant Number: P30 CA82103 (McCormick, F.)
Date of Project: 8/5/99- 5/31/12 Granting Agency: NIH NCI
Title: Cancer Center Support Grant

The Cancer Center Support Grant provides support for administration and infrastructure for the UCSF Comprehensive Cancer Center. Dr. Lanier is the Program Leader of the Cancer & Immunity Program.

Grant Number: RP-03-054-01 PI: Lewis L. Lanier
Dates of Project: 01/01/03 – 12/31/07 Granting Agency: American Cancer Society
Title: American Cancer Society Research Professorship
Amount: \$80,000 Annual Direct Costs

This is a senior professorship grant awarded to outstanding cancer researchers.

Grant Number: U01-CA105379 PI: Doug Hanahan (Co-PI: Lewis L. Lanier)
Dates of Project: 09/15/04-03/31/09 Granting Agency: NIH/NCI
Title: Immune Enhancement and Therapy of Cancer

Amount: \$75,000 Annual Direct Costs

This is an exploratory U01 grant to investigate the role of NK cells in mouse models of primary tumorigenesis.

Grant Number: P01AI64520

PI: Frances Brodsky (Lewis L. Lanier, Project Leader)

Dates of Project: 9/18/05-2/28/10 Granting Agency: NIH/NIAID

Title: Human Natural Killer Cell Biology

Amount: \$200,000/Annual Direct Costs

The objective of this grant is to understand recognition and function of human NK cells. Lewis Lanier is the Project Leader of Unit I and will be responsible for all aspects of this Unit, and for interacting with the PI and other Program Leaders in the P01. Dr. Lanier will devote 10% effort towards this grant, which will be sufficient to ensure completion of the scientific aims and administrative oversight of the Project.

Research Support - Completed

Grant Number: R01 AI52127 PI: Chris Goodnow (Co-PI: Lewis L. Lanier)
10%

Dates of Project: 09/15/01 – 6/30/07 Granting Agency: NIH NIAID

Title: Genes for Tolerance and Immunity Consortium

Amount: \$387,849 Annual Direct Costs

The objective of this grant is to generate and characterize mutant mice demonstrating defects in the immune system, which will provide models for human disease. This grant is a collaborative effort between Dr. Chris Goodnow (PI) of the Australian National University and Drs. Lewis Lanier, Art Weiss, and Jason Cyster (Co-PI). Dr. Lanier will direct the studies of mice with selective defects in NK cells and CTLs.